Kestrel Therapeutics

Executive Summary

Kestrel Therapeutics is a private, clinical-stage biotechnology company focused on developing small molecule inhibitors of protein-protein interactions for KRAS-driven cancers. Its lead candidate, KST-6051, is an oral pan-KRAS inhibitor entering Phase 1 clinical trials. Unlike mutant-specific KRAS inhibitors, KST-6051 targets all KRAS isoforms, potentially addressing a broader patient population, including those with KRAS G12C, G12D, and other mutations. The company's approach is based on proprietary insights into KRAS biology and has shown promising preclinical activity. However, as a private company with limited public information, Kestrel faces typical early-stage risks including clinical execution, financing, and regulatory uncertainties. The lack of disclosed funding or valuation data suggests the company may be operating with limited resources or seeking additional capital to advance its pipeline. Success in Phase 1 will depend on demonstrating safety and tolerability, as well as early signs of efficacy, which could position Kestrel as a key player in the evolving KRAS inhibitor landscape.

Upcoming Catalysts (preview)

• Q2 2026First patient dosed in Phase 1 trial of KST-605180% success
• Q4 2026Initial safety and pharmacokinetic data from Phase 160% success
• TBDPotential partnership or Series B financing announcement50% success